Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2793 - 2800 of 12025 results
Spotlight on ESG Investing: The Importance of Understanding Environmental, Social and Governance Factors and Their Impact on Investing
October 19, 2021| Article| Viewpoint
Privacy Implications of the Facebook Whistleblower Testimony
October 19, 2021| News
California’s Senate Bill 41: The Genetic Information Privacy Act
October 19, 2021| Blog| Viewpoint
Monthly TCPA Digest — October 2021
October 19, 2021| Article| Viewpoint
TCPA Regulatory Update — Blocking Foreign-Initiated Robocalls, Safeguarding PSAP Phone Numbers, and Blocking Spam Texts
October 19, 2021| Article| Viewpoint
TCPA Litigation Update — No Payday for Deceptive Conduct
October 19, 2021| Article| Viewpoint
FDA Begins Modernizing its Resources and Implementing Over-The-Counter Monograph User Fee Requirements
October 14, 2021| Blog| Viewpoint
Startups Can Raise From Crowdfunding Sites And Get Their Venture Capital Too
October 14, 2021| News
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|